Review articleGliomatosis cerebri: Prognosis based on current molecular markers

- 11 studies were included in the final review process.
- Significant prognostic value associated with IDH1132H mutation.
- Variable evidence surrounding the role of INA expression, MGMT promoter methylation.
- Significant limitations in the level of evidence.

This study aims to review the literature and identify key molecular markers affecting the prognosis of Gliomatosis cerebri (2) to evaluate the level of evidence and identify outstanding markers requiring further study. A literature search was conducted across 5 major databases using the key terms: “Molecular markers” AND “Gliomatosis cerebri” OR “diffuse astrocytoma.” Critical appraisal and data presentation was performed inline with the PRISMA guidelines. Following search strategy implementation, 11 studies were included in the final review process. Our data demonstrates significant prognostic value associated with IDH1132H mutation and variable evidence surrounding the role of INA expression, MGMT promoter methylation and other factors. However, there are significant limitations in the level of evidence obtained. As the genetic basis for the pathogenesis of Gliomatosis cerebri continues to widen, there is little data on markers aside from IDH1 mutation available. IDH1132H mutation has been demonstrated to have significant effect on survival, particularly in patients with Gliomatosis cerebri type 2.